ALKERMES PLC | 21,55 Euro | -0,604 -2,73 % | |
| WKN: A1JKVH ISIN: IE00B56GVS15 Ticker-Symbol: 8AK | Frankfurt | 18.06.13 | 08:00 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 13.06. | Alkermes' CEO Presents at Goldman Sachs Healthcare Conference (Transcript) | 1 | Seeking Alpha | |
| 13.06. | Alkermes Changing The Standard Of Care For Schizophrenia | 3 | Seeking Alpha | |
| 13.06. | Alkermes Up 33.0% Since SmarTrend Uptrend Call | - | SmarTrend | |
| 10.06. | A Full Pipeline At Alkermes | 3 | Seeking Alpha | |
| 05.06. | Alkermes Shares Up 33.9% Since SmarTrend's Buy Recommendation | 3 | SmarTrend | |
| 01.06. | Alkermes is Among the Companies in the Biotechnology Industry With the Highest Projected Earnings Growth | - | SmarTrend | |
| 31.05. | Alkermes Makes a Move: Down 5.0% | 1 | SmarTrend | |
| 31.05. | Alkermes Crosses Below its 10-day MA | - | SmarTrend | |
| 31.05. | Alkermes Issues Positive Results from Phase 2 Study of ALKS 5461 | - | Benzinga.com | |
| 31.05. | Alkermes Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder Met Primary Endpoint | 1 | Benzinga.com | |
| 31.05. | Alkermes (ALKS) Issues Positive Update for ALKS 5461 Phase 2 | - | StreetInsider.com | |
| 31.05. | Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU Meeting | 43 | Business Wire | |
| —Novel Mechanism Represents New Treatment Approach for Patients With Inadequate Response to Conventional Antidepressants Alkermes plc (NASDAQ: ALKS) today announced the presentation... Mehr lesen zu: Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU Meeting | ||||
| 30.05. | Alkermes plc. - 10-K/A, Annual Report | - | SEC Filings | |
| 29.05. | Encouraging Data from Alkermes | 2 | Zacks | |
| 29.05. | Alkermes' Corporate Presentation to be Webcast at Two Upcoming Conferences | 40 | Business Wire | |
| Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 11:30 a.m.... Mehr lesen zu: Alkermes' Corporate Presentation to be Webcast at Two Upcoming Conferences | ||||
| 29.05. | Alkermes' Management Presents at Deutsche Bank 38th Annual dbAccess Health Care Conference (Transcript) | - | Seeking Alpha | |
| 29.05. | A Fundamental Take On Alkermes' Turnaround Story | 2 | Seeking Alpha | |
| 28.05. | Alkermes advances schizophrenia drug candidate | - | bizjournals | |
| 28.05. | Alkermes Reports Positive Results From Phase 1 Study Of ALKS 3831 | 29 | AFX News | |
| WASHINGTON (dpa-AFX) - Alkermes plc (ALKS) reported positive results from a
phase 1 study of ALKS 3831, a drug candidate for the treatment of schizophrenia.ALKS 3831 is an investigational... Mehr lesen zu: Alkermes Reports Positive Results From Phase 1 Study Of ALKS 3831 | ||||
| 28.05. | Alkermes Announces Positive Results from Phase 1 Study of ALKS 3831 Treatment for Schizophrenia | - | Benzinga.com | |
Seite: 1 2 3 4 5 ... Weiter >>
123 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von